MEDTRONIC, INC. CRYOFLEX SURGICAL ABLATION PROBE; SURGICAL DEVICE, FOR CUTTING, COAGULATION, AND/OR ABLATION OF TISSUE, INCLUDING
|
Back to Search Results |
|
Model Number 60SF3 |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Anemia (1706); Hemorrhage/Bleeding (1888); Blood Loss (2597)
|
Event Date 09/18/2019 |
Event Type
Injury
|
Manufacturer Narrative
|
If information is provided in the future, a supplemental report will be issued.
|
|
Event Description
|
The patient had a concomitant surgical procedure of coronary artery bypass grafting (cabg) through sternotomy.During the same procedure ((b)(6) 2019) a cryoflex probe powered by a cryoconsole, and a cardioblate lp clamp powered by a cardioblate generator were used.The left atrial appendage was successfully amputated/excised.Left pulmonary vein (pv) and right pulmonary vein (pv) conduction block were not performed for patient safety.On the same day as the procedure ((b)(6) 2019) the patient experienced acute blood loss anemia which was treated with blood transfusions.The patient recovered on ((b)(6) 2019).The adverse event was deemed by the site as causally related to the concomitant procedure and possibly related to the study procedure but not related to the study devices.Cec adjudicated as possibly related to all study devices used, concomitant procedure and the study procedure.
|
|
Manufacturer Narrative
|
Additional information received reported that the left pulmonary vein (pv) and right pulmonary vein (pv) conduction block were not performed for patient safety because the heart was so massive this was not considered safe to perform.The patient required a transfusion on the (b)(6) 2019.On the (b)(6) 2019 the patient received leuko-reduced red cells, platelet pheresis, and 2 units of frozen plasma.On the (b)(6) 2019 the patient received leuko-reduced red cells.On the (b)(6) 2019 the patient received 2 units of leuko-reduced red cells.The lowest haemoglobin/haematocrit was recorded on the (b)(6) 2019, value: 5.8/17.0 levels returned to normal on (b)(6) 2019, value: 7.1/21.6.The values continued to increase from this date.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Manufacturer Narrative
|
Medtronic received additional information that the adverse event was deemed by the site as causally related to the concomitant and to the study procedure and possibly related to the cardioblate cryoflex probe and cardioblate lp clamp.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Search Alerts/Recalls
|
|
|